Pais / Región
Paises

Provincias / Departamentos
Colombia Colombia
Argentina Argentina
Canada Canada
Chile Chile
Ecuador Ecuador
España España
Guatemala Guatemala
Honduras Honduras
Mexico Mexico
Panama Panama
Paraguay Paraguay
United States United States
Uruguay Uruguay
Categorias / Industrias
Publication: 0000-00-00 00:00:00
United States SAM

6550--NEW - Access BNP Reagents

Process Number 36C25722Q0129

USA

Dates:


Notice ID:

36C25722Q0129

Department/Ind. Agency:

VETERANS AFFAIRS, DEPARTMENT OF

Sub-tier:

VETERANS AFFAIRS, DEPARTMENT OF

Sub Command:

257-NETWORK CONTRACT OFFICE 17 (36C257)

Office:

257-NETWORK CONTRACT OFFICE 17 (36C257)

General Information:


All Dates/Times are:

(utc-06:00) central standard time, chicago, usa

Updated Published Date:

(utc-06:00) central standard time, chicago, usa

Original Published Date:

0000-00-00 00:00:00

Original Response Date:

dec 20, 2021 10:00 am cst

Inactive Policy:

manual

Original Inactive Date:

jan 19, 2022

Initiative:
  • None***--***

Classification:


Product Service Code:

6550 - in vitro diagnostic substances, reagents, test kits and sets

NAICS Code:

325413 - in-vitro diagnostic substance manufacturing

Description:


Original Set Aside:

The Department of Veterans Affairs South Texas Veterans Health Care System (STVHCS), Audie L. Murphy Division and the VISN 17 Contracting (10N17/671C), 7400 Merton Minter, San Antonio, TX 78229, intends to award a firm-fixed price supply contract, for the Access BNP Reagents compatible with the Beckman Immunochemistry Instrumentation. No other types of substitute or third-party reagents will fit the need of the STVHCS for the reasons notated. BNP is one of the analytes being monitored in COVID patients in the current Pandemic. The Access BNP test is the only BNP test approved by the FDA that is exclusively made to work on our current Beckman Coulter Immunochemistry Analyzers. The BNP test is an In Vitro quantitative measurement of B-Type Natriuretic peptide (BNP) used by physicians to diagnose Congestive Heart Disease (CHD), make treatment decisions and monitor patients with Heart Failure and Acute Coronary Syndrome Please see attachment. Please submit all information and proposals to Ognian Ivanov mailto:ognian.ivanov@va.gov no later than Monday , December 20, 2021, 11:00 AM ET (10:00 AM CT).

Attachments / Links:


Document Size Updated date Download

Contact Information:


2301 E. LAMAR BLVD

ARLINGTON , TX 76006

USA

Primary Point of Contacts:

ognian.ivanov@va.gov